{
    "eid": "2-s2.0-85047305790",
    "title": "Short-term efficacy and safety of adding Ezetimibe to current regimen of lipid-lowering drugs in human immunodeficiency virus-infected Thai patients treated with protease inhibitors",
    "cover-date": "2018-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Microbiology (medical)",
            "@code": "2726",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Dyslipidemia",
        "Ezetimibe",
        "Human immunodeficiency virus (HIV)",
        "Protease inhibitor",
        "Statin"
    ],
    "authors": [
        "Krisda Boonthos",
        "Chankit Puttilerpong",
        "Thitima Pengsuparp",
        "Weerawat Manosuthi"
    ],
    "citedby-count": 2,
    "ref-count": 38,
    "ref-list": [
        "Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand",
        "Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort",
        "Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study",
        "Protease inhibitors and cardiovascular outcomes in patients with HIV-1",
        "Impact of HIV infection and HAART on serum lipids in men",
        "Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study",
        "Combination antiretroviral therapy and the risk of myocardial infarction",
        "Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy",
        "Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City",
        "Class of antiretroviral drugs and the risk of myocardial infarction",
        "Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment",
        "Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (DAD) study",
        "Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)",
        "Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group",
        "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines",
        "Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047",
        "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death",
        "Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin",
        "Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidemia",
        "Zetia: Inhibition of Niemann-Pick C1 like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia",
        "Inhibition of intestinal cholesterol absorption by ezetimibe in humans",
        "Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia",
        "Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor",
        "Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia",
        "Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions",
        "Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia",
        "Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial",
        "Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial",
        "Ezetimibe added to statin therapy after acute coronary syndromes",
        "Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin",
        "Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients",
        "Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-Infected patients receiving combination antiretroviral therapy",
        "Ezetimibe, a promising lipidlowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins",
        "Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients",
        "Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients",
        "Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nontaburi",
            "@id": "60015728",
            "affilname": "Thailand Ministry of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015728",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn University"
    ]
}